jakhals schreef op 26 november 2019 06:49:
Time to Reconsider PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF) After More Short Sellers?Posted by Winship John on November 25, 2019 at 4:45 pm
The stock of PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF) registered an increase of 2.84% in short interest. PHGUF’s total short interest was 14.48 million shares in November as published by FINRA. Its up 2.84% from 14.08M shares, reported previously. With 12,600 shares average volume, it will take short sellers 1149 days to cover their PHGUF’s short positions.
It closed at $1.35 lastly. It is down 0.00% since November 25, 2018 and is . It has by 0.00% the S&P500.
Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for treatment of rare diseases and unmet medical needs. The company has market cap of $848.05 million. The companyÂ’s lead product is Ruconest , a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It currently has negative earnings. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human Factor VIII, a natural human blood clotting factor for treating Haemophilia A.
Another recent and important Pharming Group N.V. (OTCMKTS:PHGUF) news was published by Seekingalpha.comwhich published an article titled: “Pharming: Creating New Generation Plasma-Free Medicines For Unmet Medical Needs – Seeking Alpha” on August 14, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.